San Antonio Breast Cancer Symposium: Press Releases

Home About SABCS Press Releases Media Event Photos Past Symposia Satellite Symposia Patient Advocates FAQs Contact Us

2013 Overview Registration Hotel Support & Exhibits Program Faculty Travel & Transportation

Media Contact:
Jeremy Moore
(215) 446-7109
Jeremy.Moore@aacr.org

In San Antonio:
(210) 582-7021

Press Releases > SABCS 2012

SAN ANTONIO - The 2012 CTRC-AACR San Antonio Breast Cancer Symposium will be held at the Henry B. Gonzales Convention Center in San Antonio, Texas, Dec. 4-8. Now in its 35th year, the symposium will feature new research focusing on emerging treatments in hard-to-treat populations, such as patients with triple-negative breast cancer, and new knowledge on biologic targets and prevention.

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the AACR and Baylor College of Medicine will jointly present the symposium. The driving force behind this collaboration is the shared mission of the organizations to advance progress in breast cancer research.

To help guide coverage for the news media, the AACR Communications and Public Relations Department will operate a full-service press room in Room 217A-C of the convention center. In addition, three press conferences will be held in Room 217D. Reporters who cannot attend in person can participate using the following information:

U.S./Canada (toll free): 1 (800) 446-2782
International (toll): 1 (847) 413-3235

Press Conference Schedule:

Wednesday, Dec. 5 at 7:30 a.m. CT
Hosted by Peter Ravdin, M.D., Ph.D., Director of the Breast Health Clinic at the CTRC

Higher Doses of Fulvestrant Prolonged Survival in Patients With Advanced Breast Cancer [12/5/2012 7:30 a.m. CT]
Combination of Investigational Agent and Letrozole Demonstrated Clinical Benefit in Advanced ER-positive Breast Cancer [12/5/2012 7:30 a.m. CT]
Sentinel Lymph Node Surgery After Chemotherapy Demonstrated Accuracy in Nodal Staging for Certain Patients With Breast Cancer [12/5/2012 7:30 a.m. CT]
Black Women Less Likely to Receive Improved Surgical Procedure for Breast Cancer [12/5/2012 7:30 a.m. CT]
Extending Duration of Adjuvant Tamoxifen to 10 Years Reduced Risk for Late Breast Cancer Recurrence Improved Survival [12/5/2012 7:30 a.m. CT]

Thursday, Dec. 6 at 7:30 a.m. CT
Hosted by Carlos L. Arteaga, M.D., Associate Director for Clinical Research and Director of the Breast Cancer Program at Vanderbilt Ingram Cancer Center

Young Women With Breast Cancer Were More Likely Than Older Women to Respond to Neoadjuvant Chemotherapy [12/6/2012 7:30 a.m. CT]
Chemotherapy After Complete Surgical Removal of Local or Regional Breast Cancer Recurrence Increased Survival Rates [12/6/2012 7:30 a.m. CT]
Diverse Genetic Alterations Found in Triple-negative Breast Cancers After Neoadjuvant Chemotherapy [12/6/2012 7:30 a.m. CT]
HDAC Inhibitors Sensitized Triple-negative Breast Cancer Cells to PARP Inhibition and Cisplatin Treatment [12/6/2012 7:30 a.m. CT]
Hypofractionated Radiotherapy Was Safe Effective for Early Breast Cancer Treatment at 10-year Follow-up [12/6/2012 7:30 a.m. CT]

Friday, Dec. 7 at 7:30 a.m. CT
Hosted by C. Kent Osborne, M.D., Director of the Lester and Sue Smith Breast Cancer Center at Baylor College of Medicine

Extending Adjuvant Trastuzumab Treatment Time Provided No Additional Benefit [12/7/2012 7:30 a.m. CT]
Breast Cancer Genome Sequencing Identified HER2 Mutations as Targets for Drug Treatment [12/7/2012 7:30 a.m. CT]
Cognitive Problems May Be Present Before Chemotherapy in Women With Breast Cancer [12/7/2012 7:30 a.m. CT]
Adjuvant Bevacizumab Did Not Improve Invasive Disease-free Survival Rate in Triple-negative Breast Cancer [12/7/2012 7:30 a.m. CT]
Phase III Trial Did Not Show Superiority of Eribulin Compared With Capecitabine in Metastatic Breast Cancer [12/7/2012 7:30 a.m. CT]

The 2012 CTRC-AACR San Antonio Breast Cancer Symposium will also present awards:

Two Leading Researchers to Be Honored at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium [11/28/2012]

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio